Frontiers in Bioengineering and Biotechnology

Journal Title
Frontiers in Bioengineering and Biotechnology

FRONT BIOENG BIOTECH

ISSN / eISSN
2296-4185 / 2296-4185
Aims and Scope
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.

In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.
Subject Area

MULTIDISCIPLINARY SCIENCES

CiteScore
8.30 View Trend
CiteScore Ranking
Category Quartile Rank
Medicine - Histology Q1 #8/62
Medicine - Biomedical Engineering Q1 #63/303
Medicine - Biotechnology Q1 #65/311
Medicine - Bioengineering Q1 #39/162
Web of Science Core Collection
Science Citation Index Expanded (SCIE) Social Sciences Citation Index (SSCI)
Indexed -
Category (Journal Citation Reports 2024) Quartile
BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q1
ENGINEERING, BIOMEDICAL Q2
Country/Area of Publication
Switzerland
Publisher
Frontiers Media S.A.
Annual Article Volume
1559
Open Access
YES
Contact
AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, SWITZERLAND, CH-1015
Verified Reviews
Note: Verified reviews are sourced from across review platforms and social media globally.
Seeing the call for submissions, I happened to have an article in the same field. I thought of submitting it quickly for publication. It was promptly sent for review, and the editor found three reviewers. Two of them replied via email, but their comments were not flattering. The first paragraph of the introduction clearly addressed the issues raised by the reviewers twice. Since my conclusion advocated for counter-regulation, one of the reviewers, based on their own logic, claimed that my graphical results were the opposite and gave the impression of being unreadable. Then there was an interactive review session, where I explained everything in detail, but it was still rejected. Recently, many journals under this publishing house have been calling for submissions, giving a sense of high risk.
2022-03-29
Handling Editor: xxxxxxxxxxx
Received date: 29 Nov 2022
Editorial assignment start date: 29 Nov 2022
Independent review start date: 07 Dec 2022
Interactive review activated date: 06 Jan 2023
Review finalized date: 08 Feb 2023
Final validation date: 09 Feb 2023
Frontiers currently has three risk journals, but compared to other journals, FIBB doesn't need to worry about risks for now. Overall, it is still acceptable as it is a Q2 journal in the Chinese Academy of Sciences and has already achieved Q1 in JCR. It is recommended to submit the manuscript avoiding Christmas and Chinese New Year to speed up the process. Also, the fee of $3250 is a bit expensive.
2023-02-09

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started